Curis (NASDAQ:CRIS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Curis (NASDAQ:CRIS) from a strong sell rating to a hold rating in a research note released on Wednesday,Zacks reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Curis in a research report on Monday, August 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Curis presently has a consensus rating of “Hold” and an average target price of $43.00.

Curis Price Performance

CRIS stock opened at $1.16 on Wednesday. The company has a 50 day moving average price of $3.35 and a 200 day moving average price of $9.20. Curis has a fifty-two week low of $1.11 and a fifty-two week high of $39.00. The stock has a market capitalization of $2.42 million, a PE ratio of -0.08 and a beta of 3.01.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. As a group, equities analysts expect that Curis will post -24.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CRIS. Jane Street Group LLC grew its stake in shares of Curis by 71.8% during the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 10,586 shares during the period. XTX Topco Ltd acquired a new position in Curis in the fourth quarter valued at about $26,000. Focused Wealth Management Inc acquired a new position in Curis in the second quarter valued at about $26,000. BlackRock Inc. bought a new position in Curis during the second quarter worth about $28,000. Finally, Squarepoint Ops LLC boosted its holdings in Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after buying an additional 27,343 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.